3.1.3.5: 5'-nucleotidase
This is an abbreviated version!
For detailed information about 5'-nucleotidase, go to the full flat file.
Word Map on EC 3.1.3.5
-
3.1.3.5
-
nucleoside
-
adp
-
deaminase
-
triphosphate
-
purinergic
-
ecto-5\'-nucleotidase
-
lymphocyte
-
endothelial
-
phosphodiesterase
-
ntpdases
-
agonist
-
diphosphohydrolase
-
erythrocyte
-
adenylate
-
inosine
-
platelet
-
phosphorylase
-
na+
-
cytochemical
-
glucose-6-phosphatase
-
5'-monophosphate
-
hypoxanthine
-
histochemistry
-
concanavalin
-
acetylcholinesterase
-
apyrase
-
ecto-enzymes
-
synaptosomes
-
5'-diphosphate
-
adpase
-
ecto-atpase
-
suramin
-
mg2+-atpase
-
deoxycytidine
-
k+-atpase
-
dpcpx
-
dipyridamole
-
ouabain-sensitive
-
purinoceptors
-
phosphomonoesterase
-
sarcolemma
-
plasma-membrane
-
neuromodulator
-
antivenoms
-
ppads
-
ehna
-
8-cyclopentyl-1,3-dipropylxanthine
-
ectonucleotide
-
8-phenyltheophylline
-
nutrition
-
hgprt
-
medicine
-
pharmacology
- 3.1.3.5
- nucleoside
- adp
- deaminase
- triphosphate
-
purinergic
-
ecto-5\'-nucleotidase
- lymphocyte
- endothelial
- phosphodiesterase
- ntpdases
- agonist
-
diphosphohydrolase
- erythrocyte
- adenylate
- inosine
- platelet
- phosphorylase
- na+
-
cytochemical
- glucose-6-phosphatase
- 5'-monophosphate
- hypoxanthine
-
histochemistry
-
concanavalin
- acetylcholinesterase
- apyrase
-
ecto-enzymes
-
synaptosomes
- 5'-diphosphate
- adpase
- ecto-atpase
- suramin
- mg2+-atpase
- deoxycytidine
-
k+-atpase
- dpcpx
- dipyridamole
-
ouabain-sensitive
-
purinoceptors
- phosphomonoesterase
- sarcolemma
-
plasma-membrane
-
neuromodulator
- antivenoms
-
ppads
- ehna
- 8-cyclopentyl-1,3-dipropylxanthine
-
ectonucleotide
-
8-phenyltheophylline
- nutrition
- hgprt
- medicine
- pharmacology
Reaction
Synonyms
5'-adenylic phosphatase, 5'-AMP nucleotidase, 5'-AMPase, 5'-ectonucleotidase, 5'-mononucleotidase, 5'-NT, 5'-NT-1, 5'-NT-2, 5'-NT-3, 5'-NT-4, 5'-nucleotidase, 5'-nucleotidase A, 5'-nucleotidase I, 5'-nucleotidase II, 5'Nase, 5'nucleotidase, 5nA, 5NT, adenosine 5'-monophosphatase, adenosine 5'-phosphatase, adenosine monophosphatase, AMP phosphatase, AMP phosphohydrolase, AMP-selective 5'-nucleotidase, AMPase, c-N-I, c-N-II, Cant1, CD73, CD73 antigen, CD73/ecto-5'-nucleotidase, class C acid phosphatase, cN-I, cN-IA, cN-II, cN-III, cNI, cNII, cNIIIB nucleotidase, cytoplasmic 5'-nucleotidase II, cytoplasmic 5'-nucleotidase II (IMP-selective or GMP/IMP-selective), cytoplasmic 5'-nucleotidase III, cytoplasmic 5'-nucleotidase-I (AMP-selective), cytosolic 5'-nucleotidase, cytosolic 5'-nucleotidase II, cytosolic 5'-nucleotidase/phosphotransferase, E-5'-Nu, e-5NT, e-N, e5'-NT, e5'NT, ecto 5'-NT, ecto 5'-nucleotidase, ecto-5' nucleotidase, ecto-5'-NT, ecto-5'-NT/CD73, ecto-5'-nucleotidase, ecto-5'-nucleotidase/CD73, ecto-5'nucleotidase, ecto-5-NT, ecto-5-nucleotidase, ecto-nucleotidase, ectonuceotidase, ectonucleotidase, ectonucleotidase CD73, eN, eNs, eNT, GA-AMPase, high Km 5'-nucleotidase, high-Km 5'-NT, hppA gene product, IMP 5'-nucleotidase, IMP-GMP 5'-nucleotidase, IMP-GMP specific nucleotidase, IMP-specific, high Km 5'-nucleotidase, IMP/GMP selective 5'-NT, Isn1, membrane-bound 5'-nucleotidase, More, NMN 5'-nucleotidase, NT5C3A, NT5E, P5'N-1, Phm8, Pho5, PM-AMPase, PN-1, PN-I, purine 5'-NT, purine 5'-nucleotidase, pyrimidine 5'-nucleotidase, Sdt1, snake venom 5'-nucleotidase, soluble calcium-activated nucleotidase 1, thymidine monophosphate nucleotidase, type II cytosolic 5'-nucleotidase, UMPase, UMPH-1, uridine 5'-nucleotidase, uridine monophosphate hydrolase-1, UshA, XF_2089, YutF
ECTree
3.1.3.5 5'-nucleotidaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 3.1.3.5 - 5'-nucleotidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(2E)-5-(5-methylfuran-2-yl)-N-(2-methylphenyl)-3-oxo-2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide
67% inhibition at 0.005 mM
(2R,4S,5R)-1-[5-(2-fluoro-2-phosphonoethyl)tetrahydro-4-hydroxy-2-furyl]thymine
-
-
(2R,4S,5R)-1-[tetrahydro-4-hydroxy-5-(2-phosphonoethyl)-2-furyl]thymine
-
-
(2Z)-2-[[3-(3-fluoro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl]methylidene]-6-[(4-methylphenyl)methyl]-7H-[1,3]thiazolo[3,2-b][1,2,4]triazine-3,7(2H)-dione
61% inhibition at 0.005 mM
1,10-phenanthroline
-
inhibition of cytosolic and membrane-bound enzyme
1-(6-deoxy-6-phosphono-beta-D-allofuranosyl)-5-(2-(E)-phenylvinyl)-cytosine
-
1-amino-2-methyl-4-(phenylamino)anthracene-9,10-dione
-
4% inhibition at 1 mM
1-amino-4-(1-anthracenylamino)-9,10-dioxo-9,10 dihydroanthracene-2-sulfonate
-
-
1-amino-4-(1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
competitive mechanism
1-amino-4-(2,3-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
39% inhibition at 1 mM
1-amino-4-(2,4-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
47% inhibition at 1 mM
1-amino-4-(2,5-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
26% inhibition at 1 mM
1-amino-4-(2-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
47% inhibition at 1 mM
1-amino-4-(2-anthracenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
competitive mechanism
1-amino-4-(2-carboxy-4-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
52% inhibition at 1 mM
1-amino-4-(2-carboxy-4-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(2-carboxy-5-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
27% inhibition at 1 mM
1-amino-4-(2-carboxy-5-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
60% inhibition at 1 mM
1-amino-4-(2-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(2-ethoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
56% inhibition at 1 mM
1-amino-4-(2-hydroxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(2-methoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
9% inhibition at 1 mM
1-amino-4-(2-methyl-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(2-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
33% inhibition at 1 mM
1-amino-4-(2-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(2-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
14% inhibition at 1 mM
1-amino-4-(3,4-dimethoxyphenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
44% inhibition at 1 mM
1-amino-4-(3-amino-2,4,6-trimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(3-amino-4-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(3-amino-5-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
44% inhibition at 1 mM
1-amino-4-(3-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
31% inhibition at 1 mM
1-amino-4-(3-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
26% inhibition at 1 mM
1-amino-4-(3-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-amino-3-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-bromo-2-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
56% inhibition at 1 mM
1-amino-4-(4-bromophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-carboxymethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
26% inhibition at 1 mM
1-amino-4-(4-chlorophenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
62% inhibition at 1 mM
1-amino-4-(4-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-ethoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
31% inhibition at 1 mM
1-amino-4-(4-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-hydroxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-phenoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(4-phenylaminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
37% inhibition at 1 mM
1-amino-4-(4-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(5-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(6-carboxy-2-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(6-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(8-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(9-phenanthrenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
58% inhibition at 1 mM
1-amino-4-(benzylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
43% inhibition at 1 mM
1-amino-4-(cyclohexylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
-
1-amino-4-(cyclopentylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
51% inhibition at 1 mM
1-amino-4-(isopropylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
15% inhibition at 1 mM
1-amino-4-(phenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
53% inhibition at 1 mM
1-amino-4-[4-(diethoxyphosphoryl)methylphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
-
28% inhibition at 1 mM
1-tert-butyl-5-chloro-6-(2-hydroxy-5-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
2,2'-(2-(2-((2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-carboxamido)ethylamino)-2-oxoethylazanediyl) diacetic acid
nucleotide-derived inhibitor
2,3,5-tri-O-benzyl-1-O-(4-nitrobenzoyl)-D-arabinofuranose
68% inhibition at 0.005 mM
2-((4'-cyano-4,4''-dimethoxy-[1,1':3',1''-terphenyl]-5'-yl)thio)-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)acetamide
73% inhibition at 0.005 mM
2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-[4-[1-(4-methylbenzoyl)-2,3-dihydro-1H-indol-5-yl]-5-sulfanyl-1,3-thiazol-2-yl]acetamide
74% inhibition at 0.005 mM
2-fluoroadenine-9-beta-D-arabinofuranoside
1 mM, 70% inhibition with 5 mM 5'-AMP as substrate
3-[4,5-di([1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]-1H-indole
93% inhibition at 0.005 mM
4-(4-[1-[(3-chlorophenyl)methyl]-4-hydroxy-1H-[1,2,3]triazolo[4,5-c]pyridin-6-yl]piperidine-1-sulfonyl)-N-cycloheptylbenzene-1-sulfonamide
63% inhibition at 0.005 mM
4-(6-[[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methyl]-1H-benzimidazol-2-yl)aniline
78% inhibition at 0.005 mM
5'-deoxy-7-methyl-5'-(4-phosphono-1H-pyrazol-1-yl)guanosine
-
moderately potent inhibitor
6-(4-ethoxyphenyl)-3-(4-methylphenyl)-N-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
65% inhibition at 0.005 mM
6-N,N-diethyl-D-beta-gamma-dibromomethylene adenosine triphosphate
originally named FPL 67156 or ARL 67156, 28% inhibition at 0.1 mM
clomipramine
-
enzymatic activity is decreased by the antidepressant clomipramine after in vitro exposure
ethyl 4-(2-((4'-cyano-4''-methoxy-4-methyl-[1,1':3',1''-terphenyl]-5'-yl)thio)acetamido)benzoate
80% inhibition at 0.005 mM
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate
monastrol
ethyl 4-[4-(dimethylamino)phenyl]-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate
LaSOM 63
Ly-294002
-
0.01 mM LY-294002 abolishes lipopolysaccharide-induced ecto-5'-nucleotidase activity
N-(4-methylcyclohexyl)-1-(2-phenyl-1H-benzimidazole-5-sulfonyl)piperidine-3-carboxamide
17% inhibition at 0.005 mM
N-[4-[5-([2-[2-(4-methoxybenzoyl)hydrazinyl]-2-oxoethyl]sulfanyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methylbenzene-1-sulfonamide
64% inhibition at 0.005 mM
p-chloromercuribenzoate
-
inhibition of cytosolic and membrane-bound enzyme
sertraline
-
enzymatic activity is decreased by the antidepressant sertraline after in vitro exposure
sodium 1-amino-4-(2-carboxy-4-fluoroanilino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
PSB-0952
sodium 1-amino-4-anilino-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
AB-25
sodium 1-amino-4-[(anthracen-2-yl)amino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate
PSB-0963
sodium 1-amino-9,10-dioxo-4-(phenylamino)-9,10-dihydroanthracene-2-sulfonate
-
-
Specific protein inhibitor
-
the periplasmic enzyme has a specific protein inhibitor located in the cytoplasm. The physiological role of the inhibitor is to protect the intracellular nucleotide pool from any cytoplasmic 5'-nucleotidase activity
-
tetrasodium 4-[[4-([4-[(4-amino-9,10-dioxo-3-sulfonato-9,10-dihydroanthracen-1-yl)amino]-2-sulfonatophenyl]amino)-6-chloro-1,3,5-triazin-2-yl]amino]benzene-1,2-disulfonate
-
-
1-tert-butyl-1H-benzofuro[3,2-b]pyrrolo[3,2-e]pyridine-3-carbonitrile
-
1-tert-butyl-5-chloro-6-(2-hydroxy-5-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
-
1-tert-butyl-5-chloro-6-(2-hydroxy-5-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
-
1-tert-butyl-5-chloro-6-(2-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
-
1-tert-butyl-5-chloro-6-(2-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
-
2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol
-
2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol
-
2-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol
-
2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol
-
2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol
-
2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol
-
2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol
-
3-(2-(3-methoxy-4-phenoxybenzylideneamino)thiazol-4-yl)-2H-chromen-2-one
-
-
4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonic acid
-
compound shows high cytotoxicity on H157 cells, with about 72% at 100 mM final concentration
5-chloro-3-methyl-1-phenyl-6-(2-propoxyphenyl)-1H-pyrazolo[3,4-b]pyridine
-
5-chloro-3-methyl-1-phenyl-6-(2-propoxyphenyl)-1H-pyrazolo[3,4-b]pyridine
-
5-chloro-6-(2-(heptyloxy)phenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine
-
5-chloro-6-(2-(heptyloxy)phenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine
-
5-chloro-6-(2-hydroxy-5-methylphenyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-ol
-
5-chloro-6-(2-hydroxy-5-methylphenyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-ol
-
5-chloro-6-(2-hydroxyphenyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-ol
-
5-chloro-6-(2-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine
-
5-chloro-6-(2-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine
-
6-amino-4-hydroxynaphthalene-2-sulfonic acid
-
most potent inhibitor of the screen
6-amino-4-hydroxynaphthalene-2-sulfonic acid
-
most potent inhibitor of the screen
6-chloro-7-(2-hydroxy-5-methylphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
-
6-chloro-7-(2-hydroxy-5-methylphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
-
6-chloro-7-(2-hydroxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
-
6-chloro-7-(2-hydroxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
-
6-chloro-7-(2-hydroxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione
-
7-methoxy-3-methyl-1-phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine
-
adenosine 5'-(alpha,beta-methylene)diphosphate
-
specific inhibitor, complete inhibition at 0.5 mM
adenosine 5'-(alpha,beta-methylene)diphosphate
-
treatment with 0.001 mM adenosine 5'-(alpha,beta-methylene)diphosphate, a competitive ecto-5'-NT/CD73 inhibitor, causes a significant reduction of 30% in glioma cell proliferation, the inhibitory effect on cell proliferation caused by adenosine 5'-(alpha,beta-methylene)diphosphate is reverted by cotreatment with nitrobenzylthioinosine and dipyridamole
adenosine 5'-(alpha,beta-methylene)diphosphate
-
treatment with 0.001 mM adenosine 5'-(alpha,beta-methylene)diphosphate, a competitive ecto-5'-NT/CD73 inhibitor, causes a significant reduction of 30% in glioma cell proliferation, the inhibitory effect on cell proliferation caused by adenosine 5'-(alpha,beta-methylene)diphosphate is reverted by cotreatment with nitrobenzylthioinosine and dipyridamole
Ca2+
-
gradual decrease in enzyme activity in the presence of 1-6 mM of Ca2+
concanavalin A
-
upon blockade of enzyme by concanavalin A, the strength of adhesion to different extracellular matrix proteins is not altered, but at the same time the invasion ability of the cells is decreased
-
EDTA
restoration of activity by addition of divalent cations: Cu2+, Ni2+, Co2+ or Mg2+
Fe2+
-
oxidative inactivation in a Fe2+/GSH system may be related to the selective association of Fe2+ and thiols to the enzyme molecule
Fe2+
-
the enzyme is susceptible to Fe2+-ion catalyzed oxidative modification. Among the examined chelators it is only deferoxamine and Na-citrate that exert a fully protective and reactivating ability, among the antioxidants it is only GSH, among the metal cations it is only Mn2+
fluoxetine
-
chronic treatment with 10mg/kg fluoxetine causes a 42% inhibition of AMP hydrolysis
HgCl2
-
63% inhibition at 1 mM, decreases AMP hydrolysis in a non-competitive manner
nortriptyline
-
chronic treatment with 10mg/kg nortriptyline causes a 30% inhibition of AMP hydrolysis
Zn2+
-
3.0 mM, 75% inhibition of recombinant enzyme, 20% inhibition of native enzyme
Zn2+
about 30% enzymatic activity is achieved at 0.05 mM, and the activity drops further to about 15% for 0.5 mM or higher concentrations of Zn2+
additional information
-
ethanol causes no changes on 5'-nucleotidase activity in vivo
-
additional information
-
methanol does not cause any significant alteration on ecto-5'-nucleotidase activity
-
additional information
-
not inhibited by haloperidol, sulpiride and olanzapine
-
additional information
no substrate inhibition by p-nitrophenyl phosphate
-
additional information
-
no substrate inhibition by p-nitrophenyl phosphate
-
additional information
-
in vitro and short-term in vivo treatment with fluoxetine and nortriptyline causes no change in activity
-
additional information
-
AMP hydrolysis by ecto-5'-nucleotidase is not affected by levamisole and tetramisole
-
additional information
-
insensitive to levamisole, tetramisole and adenosine 5'-[alpha-beta-methylene]diphosphate
-
additional information
-
no inhibition of the enzyme by phosphatase inhibitors. i.e. sodium orthovanadate and sodium fluoride
-
